A MicroRNA Risk Score Model Predicts The Prognosis In Colon Adenocarcinoma

Objective: To identify microRNAs related to the prognosis of colon adenocarcinoma(COAD)and construct a microRNA risk score model to improve the survival prediction of patients with COAD by using the information of COAD in The Cancer Genome Atlas(TCGA)database.Methods: Data on the expression of microRNAs and relevant clinical information were obtained from TCGA database and screened out the differentially expressed microRNAs between COAD and adjacent tissues,and then the entire COAD data set was randomly divided into a training set and a validation set.In the training set,COX-LASSO(Least absolute shrinkage and selection operator)analysis was used to screen out microRNAs related to prognosis,and a risk scoring model was constructed.The prognostic ability of the model was evaluated by C index,Kaplan-Meier analysis,receiver operating characteristic curve(ROC)and area under the curve(AUC)in both the validation set and the COAD data set.Results: A total of 271 differentially expressed microRNAs were screened out.COX-LASSO analysis identified 5 microRNAs:hsa-mi R-1255 a,hsa-mi R-34 b,hsa-mi R-3684,hsa-mi R-3917,hsa-mi R-6854,which related to the prognosis of COAD,and constructed a risk score model based on them.The C index of the model was0.827.The risk score of each sample in both the validation set and the COAD data set was calculated according to the microRNA risk score model,which was divided into high risk group and low risk group according to the median risk value.Kaplan-Meier survival curve showed that both the survival rate of the high risk group were worse than that of the low risk group(P< 0.01).The prediction efficiency of TNM stage and microRNA risk score model was compared by AUC,and the AUC in the validation set was 0.756、0.598,the AUC in the COAD data set 0.783、0.674.In stratified analysis,the model could still accurately predict the prognosis of colon adenocarcinoma.Conclusions: We constructed a microRNA risk score model based on 5microRNAs that was better than TNM staging,which may assisted clinicians to evaluate prognosis more accurately and optimize treatment strategies.